The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
INTEGRATE: A randomized phase II double-blind placebo-controlled study of regorafenib in refractory advanced esophagogastric cancer (AOGC)—A study by the Australasian Gastrointestinal Trials Group (AGITG).
Nick Pavlakis
Consultant or Advisory Role - Bayer
David Goldstein
Consultant or Advisory Role - Bayer (U)
Katrin Marie Sjoquist
No relevant relationships to disclose
Andrew Martin
No relevant relationships to disclose
Eric Tsobanis
No relevant relationships to disclose
Sonia Yip
No relevant relationships to disclose
Jenny Shannon
No relevant relationships to disclose
Matthew E. Burge
No relevant relationships to disclose
Michelle F. Cronk
No relevant relationships to disclose
Niall C. Tebbutt
Consultant or Advisory Role - Bayer
Andrew Strickland
No relevant relationships to disclose
Lara Rachel Lipton
No relevant relationships to disclose
Timothy Jay Price
Consultant or Advisory Role - Merck (U)
Louise M. Nott
No relevant relationships to disclose
Dean Laurence Harris
No relevant relationships to disclose
Margot J. Burnell
No relevant relationships to disclose
Thierry Alcindor
Consultant or Advisory Role - Bayer; Roche
Honoraria - Bayer; Roche
Yung-Jue Bang
Research Funding - Bayer
Yoon-Koo Kang
Consultant or Advisory Role - Bayer
Honoraria - Bayer
Research Funding - Bayer
Christopher J. O'Callaghan
No relevant relationships to disclose